

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 September 2017

Cumulative for August and September 2017



Contents

Summary of decisions effective 1 September 2017	3
Section H changes to Part II	5
Index	12

Summary of decisions

EFFECTIVE 1 SEPTEMBER 2017

- Aminophylline (DBL Aminophylline) inj 25 mg per ml, 10 ml ampoule
 - price increase and addition of HSS
- Enoxaparin sodium (Clexane) inj 20 mg in 0.2 ml, 40 mg in 0.4 ml, 60 mg in 0.6 ml, 80 mg in 0.8 ml, 100 mg in 1 ml, 120 mg in 0.8 ml and 150 mg in 1 ml syringe – price decrease
- Ergometrine maleate (DBL Ergometrine) inj 500 mcg per ml, 1 ml ampoule
 - price increase and addition of HSS
- Fluticasone (Floair) aerosol inhaler 50 mcg per dose, 125 mcg per dose and 250 mcg per dose – price decrease
- Fluticasone with salmeterol (RexAir) aerosol inhaler 50 mcg with salmeterol 25 mcg and 125 mcg with salmeterol 25 mcg – price decrease
- Losartan potassium (Losartan Actavis) tab 12.5 mg, 25 mg, 50 mg and 100 mg
 - price decrease and addition of HSS
- Metformin hydrochloride (Apotex) tab immediate-release 850 mg – to be delisted 1 February 2018
- Neostigmine metilsulfate (AstraZeneca) inj 2.5 mg per ml, 1 ml ampoule
 - addition of HSS
- Octreotide (DBL Octreotide) inj 50 mcg per ml, 1 ml ampoule – price increase, amended brand name and addition of HSS
- Octreotide (DBL Octreotide) inj 100 mcg per ml and 500 mcg per ml, 1 ml ampoule – price decrease, amended brand name and addition of HSS
- Oseltamivir tab 75 mg and powder for oral suspension 6 mg per ml – addition of note
- Piperacillin with tazobactam (Hospira) inj 4 g with tazobactam 0.5 g vial
 - to be delisted 1 January 2018
- Prednisolone acetate (Prednisolone-AFT) eye drops 1% – HSS suspended
- Propranolol (Apo-Propranolol) tab 10 mg and 40 mg – new listing of new Pharmacodes
- Salmeterol (Meterol) aerosol inhaler 25 mcg per dose – price decrease
- Sodium chloride (InterPharma) inj 0.9%, 5 ml ampoule – HSS suspended
- Sodium nitroprusside (Ketostix) test strip – new listing
- Sodium nitroprusside (Accu-Chek Ketur-Test) test strip – to be delisted 1 March 2018
- Suxamethonium chloride (AstraZeneza) inj 50 mg per ml. 2 ml ampoule
 - addition of HSS

Summary of decisions – effective 1 September 2017 (continued)

- Zanamivir (Relenza Rotadisk) powder for inhalation 5 mg – addition of note
- Zinc and castor oil (healthE) oint, BP – price decrease and addition of HSS

		Price (ex man. Excl. GST)		Brand or Generic Manufacturer
		\$	Per	

Section H changes to Part II

Effective 1 September 2017

ALIMENTARY TRACT AND METABOLISM

18	METFORMIN HYDROCHLORIDE (delisting)			
	Tab immediate-release 850 mg.....	7.82	500	Apotex
Note – Apotex tab immediate-release 850 mg to be delisted from 1 February 2018.				

BLOOD AND BLOOD FORMING ORGANS

34	ENOXAPARIN SODIUM (↓ price)			
	Inj 20 mg in 0.2 ml syringe.....	27.93	10	Clexane
	Inj 40 mg in 0.4 ml syringe.....	37.27	10	Clexane
	Inj 60 mg in 0.6 ml syringe.....	56.18	10	Clexane
	Inj 80 mg in 0.8 ml syringe.....	74.90	10	Clexane
	Inj 100 mg in 1 ml syringe.....	93.80	10	Clexane
	Inj 120 mg in 0.8 ml syringe.....	116.55	10	Clexane
	Inj 150 mg in 1 ml syringe.....	133.20	10	Clexane
40	SODIUM CHLORIDE (HSS suspended)			
	Inj 0.9%, 5 ml ampoule – 1% DV Mar-17 to 2019 31 Aug 2017.....	7.00	50	InterPharma

CARDIOVASCULAR SYSTEM

43	LOSARTAN POTASSIUM (↓ price and addition of HSS)			
	Tab 12.5 mg – 1% DV Nov-17 to 2020	1.39	84	Losartan Actavis
	Tab 25 mg – 1% DV Nov-17 to 2020	1.63	84	Losartan Actavis
	Tab 50 mg – 1% DV Nov-17 to 2020	2.00	84	Losartan Actavis
	Tab 100 mg – 1% DV Nov-17 to 2020	2.31	84	Losartan Actavis
46	PROPRANOLOL (new listing)			
	Tab 10 mg	3.65	100	Apo-Propranolol
	Tab 40 mg	4.65	100	Apo-Propranolol
	Note – This is the listing of new Pharmacodes for Apo-Propranolol tab 10 mg, 2525941 and 40 mg, 2525968.			

DERMATOLOGICALS

56	ZINC AND CASTOR OIL (↓ price and addition of HSS)			
	Oint, BP – 1% DV Nov-17 to 2020.....	1.26	20 g	healthE

GENITO-URINARY SYSTEM

63	ERGOMETRINE MALEATE (↑ price and addition of HSS)			
	Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	105.00	5	DBL Ergometrine

		Price (ex man. Excl. GST)		Brand or Generic Manufacturer
		\$	Per	

Changes to Section H Part II – effective 1 September 2017 (continued)

INFECTIONS

80	PIPERACILLIN WITH TAZOBACTAM (delisting) → Inj 4 g with tazobactam 0.5 g vial	5.84	1	Hospira Note – Hospira inj 4 g with tazobactam 0.5 g vial to be delisted from 1 January 2018.
96	OSELTAMIVIR (additional note) Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community under Rule 8 of Section H is not permitted. → Tab 75 mg → Powder for oral suspension 6 mg per ml			
96	ZANAMIVIR (additional note) Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community under Rule 8 of Section H is not permitted. → Powder for inhalation 5 mg	37.38	20 dose	Relenza Rotadisk

MUSCULOSKELETAL SYSTEM

99	NEOSTIGMINE METILSULFATE (addition of HSS) Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	98.00	50	AstraZeneca
106	SUXAMETHONIUM CHLORIDE (addition of HSS) Inj 50 mg per ml, 2 ml ampoule – 1% DV Nov-17 to 2020	78.00	50	AstraZeneca

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

149	OCTREOTIDE (↑ price, amended brand name and addition of HSS) Inj 50 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	30.64	5	DBL Octreotide
149	OCTREOTIDE (↓ price, amended brand name and addition of HSS) Inj 100 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	18.69	5	DBL Octreotide

Inj 500 mcg per ml, 1 ml ampoule
– 1% DV Nov-17 to 2020

72.50	5	DBL Octreotide
-------	---	----------------

RESPIRATORY SYSTEM AND ALLERGIES

193	FLUTICASONE (↓ price) Aerosol inhaler 50 mcg per dose	4.68	120 dose	Floair
	Aerosol inhaler 125 mcg per dose	7.22	120 dose	Floair
	Aerosol inhaler 250 mcg per dose	10.18	120 dose	Floair
194	SALMETEROL (↓ price) Aerosol inhaler 25 mcg per dose	9.90	120 dose	Meterol
194	FLUTICASONE WITH SALMETEROL (↓ price) Aerosol inhaler 50 mcg with salmeterol 25 mcg	14.58	120 dose	RexAir
	Aerosol inhaler 125 mcg with salmeterol 25 mcg	16.83	120 dose	RexAir

		Price (ex man. Excl. GST)	Brand or Generic Manufacturer
		\$	Per

Changes to Section H Part II – effective 1 September 2017 (continued)

195 AMINOPHYLLINE (↑ price and addition of HSS)
Inj 25 mg per ml, 10 ml ampoule
– 1% DV Nov-17 to 2020 124.37 5 DBL Aminophylline

SENSORY ORGANS

197 PREDNISOLONE ACETATE (HSS suspended)
Eye drops 1% – 1% DV Jan-17 to 2019 31 Aug 2017 3.93 10 ml Prednisolone- AFT

PART III - OPTIONAL PHARMACEUTICALS

237	SODIUM NITROPRUSSIDE (new listing) Test strip.....	12.00	50 strip	Ketostix
237	SODIUM NITROPRUSSIDE (delisting) Test strip.....	6.00	50 strip	Accu-Chek Ketur-Test Note – Accu-Chek Ketur-Test, test strips to be delisted from 1 March 2018.

Effective 1 August 2017

ALIMENTARY TRACT AND METABOLISM

15	RANITIDINE (↑ price and addition of HSS) Tab 150 mg – 1% DV Oct-17 to 2020 12.91 500 Ranitidine Relief Tab 300 mg – 1% DV Oct-17 to 2020 18.21 500 Ranitidine Relief Oral liq 150 mg per 10 ml – 1% DV Oct-17 to 2020 5.14 300 ml Peptisoothe
19	ISPAGHULA (PSYLLIUM) HUSK (↑ price and addition of HSS) Powder for oral soln – 1% DV Oct-17 to 2020 6.05 500 g Konsyl-D
25	NYSTATIN (brand change) Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020 1.95 24 ml Nilstat Note – m-Nystatin oral liquid 100,000 u per ml to be delisted from 1 October 2017.
27	PYRIDOXINE HYDROCHLORIDE (↑ price and addition of HSS) Tab 50 mg – 1% DV Oct-17 to 2020 13.63 500 Apo-Pyridoxine
27	COLECALCIFEROL (↓ price and addition of HSS) Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020 2.50 12 Vit.D3

BLOOD AND BLOOD FORMING ORGANS

35 TRISODIUM CITRATE CITRATE SODIUM (amended chemical name and presentation)
Inj 4% (**200 mg per 5 ml**), 5 ml ampoule
Inj 46.7% (**2.36 g per 5 ml**), 5 ml ampoule
Inj 46.7% (**1.4 g per 3 ml**), 3 ml syringe

		Price (ex man. Excl. GST)		Brand or Generic Manufacturer
		\$	Per	

Changes to Section H Part II – effective 1 August 2017 (continued)

38	GLUCOSE [DEXTROSE] (addition of HSS)			
	Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020 (↑ price).....	29.50	5	Biomed
	Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020	14.50	1	Biomed

CARDIOVASCULAR SYSTEM

45	BISOPROLOL FUMARATE (↑ price)			
	Tab 2.5 mg	1.18	30	Bosvate
	Tab 5 mg	1.72	30	Bosvate
	Tab 10 mg	3.13	30	Bosvate
50	NICOTINIC ACID (↑ price and addition of HSS)			
	Tab 50 mg – 1% DV Oct-17 to 2020	4.12	100	Apo-Nicotinic Acid
	Tab 500 mg – 1% DV Oct-17 to 2020	17.89	100	Apo-Nicotinic Acid
50	ISOSORBIDE MONONITRATE (↑ price and addition of HSS)			
	Tab 20 mg – 1% DV Oct-17 to 2020	18.80	100	Ismo-20

DERMATOLOGICALS

55	SULPHADIAZINE SILVER SULFADIAZINE SILVER (amended chemical name)			
	Crm 1% – 1% DV Aug-17 to 2020.....	10.80	50 g	Flamazine
56	PERMETHRIN (↑ price and addition of HSS)			
	Lotn 5% – 1% DV Oct-17 to 2020	3.69	30 ml	A-Scabies
57	EMULSIFYING OINTMENT (addition of HSS)			
	Oint BP – 1% DV Oct-17 to 2020	1.84	100 g	Jaychem
	Note: DV limit applies to pack sizes of less than 200 g.			
	Oint BP, 500 g – 1% DV Oct-17 to 2020 (↑ price).....	3.59	500 g	AFT
	Note: DV limit applies to pack sizes of greater than 200 g.			
59	PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCIN (↑ price and addition of HSS)			
	Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020	3.86	500 ml	Pinetarsol
	Note – Pinetarsol soln 2.3% with trolamine laurilsulfate and fluorescein, 1,000 ml pack to be delisted from 1 October 2017.			

GENITO-URINARY SYSTEM

63	OESTRIOL (new listing and addition of HSS)			
	Crm 1 mg per g with applicator – 1% DV Oct-17 to 2020.....	6.62	15 g	Ovestin
	Pessaries 500 mcg – 1% DV Oct-17 to 2020	6.86	15	Ovestin

HORMONE PREPARATIONS

67	DEXAMETHASONE PHOSPHATE (delisting)			
	Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-16 to 2019	12.59	5	Max Health
	Note – Max Health inj 4 mg per ml, 2 ml ampoule, 5 inj pack to be delisted from 1 September 2017. The 10 inj pack size remains listed.			

→ Restriction

8 (Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2017 (continued)

- 75 DESMOPRESSIN ACETATE (↑ price and addition of HSS)
Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020 23.95 6 ml Desmopressin-PHT

INFECTIOUS DISEASES

- | | | | | |
|----|--|----------|--------|------------------------------|
| 79 | CLARITHROMYCIN (new listing)
→ Inj 500 mg vial..... | 12.04 | 1 | Klacid |
| 79 | CLARITHROMYCIN (HSS delayed and ↓ price)
→ Inj 500 mg vial – 1% DV Sep-17 to 2020..... | 12.04 | 1 | Martindale |
| 80 | AMOXICILLIN WITH CLAVULANIC ACID (↓ price and addition of HSS)
Tab 500 mg with clavulanic acid 125 mg
– 1% DV Oct-17 to 2020..... | 1.88 | 20 | Augmentin |
| 82 | AZTREONAM (↑ price)
→ Inj 1 g vial..... | 182.46 | 5 | Azactam |
| 83 | TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE] (↑ price and addition of HSS)
Oral liq 8 mg with sulphamethoxazole
40 mg per ml – 1% DV Oct-17 to 2020..... | 2.97 | 100 ml | Deprim |
| 97 | PEGYLATED INTERFERON ALFA-2A (↓ price and addition of HSS)
→ Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020 | 500.00 | 4 | Pegasys |
| 97 | PEGYLATED INTERFERON ALFA-2A (delisting delayed)
→ Inj 180 mcg prefilled syringe (4)
with ribavirin tab 200 mg (112)..... | 1,159.84 | 1 | Pegasys RBV Combination Pack |

Note – Pegasys RBV Combination Pack inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) delisted delayed until further notice.

MUSCULOSKELETAL SYSTEM

- 107 CELECOXIB (amended restriction)
Note – The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.
Cap 100 mg – 1% DV Aug-17 to 2020 3.63 60 Celecoxib Pfizer
Cap 200 mg – 1% DV Aug-17 to 2020 2.80 30 Celecoxib Pfizer

**Restricted
Initiation**
For preoperative and/or postoperative use for a total of up to 8 days' use.

- 107 ETORICOXIB (amended restriction)
→ Tab 30 mg
→ Tab 60 mg
→ Tab 90 mg
→ Tab 120 mg

Restricted
Initiation
For preoperative and/or postoperative use for a total of up to 8 days' use.
For in-vivo investigation of allergy only.

Products with Hospital Supply Status (HSS) are in bold.
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

		Price (ex man. Excl. GST)		Brand or Generic Manufacturer
		\$	Per	

Changes to Section H Part II – effective 1 August 2017 (continued)

108	NAPROXEN (delisting)			
	Tab long-acting 750 mg – 1% DV Jun-15 to 2018.....	18.00	90	Naprosyn SR 750
	Tab long-acting 1 g – 1% DV Jun-15 to 2018.....	21.00	90	Naprosyn SR 1000
Note – Naprosyn SR 750 tab long-acting 750 mg and Naprosyn SR 1000 tab long-acting 1 g, 90 tab pack to be delisted from 1 October 2017. The 28 tab pack remains listed.				

NERVOUS SYSTEM

112	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (brand change and amended presentation description)			
	Oral (viscous gel) soln 2% – 1% DV Oct-17 to 2020	38.00	200 ml	Mucosoothe
Note – Xylocaine Viscous oral (gel) soln 2% to be delisted from 1 October 2017.				
114	FENTANYL (addition of HSS)			
	Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020 (↑ price).....	2.95	5	Fentanyl Sandoz
	Patch 25 mcg per hour – 1% DV Oct-17 to 2020.....	3.66	5	Fentanyl Sandoz
	Patch 50 mcg per hour – 1% DV Oct-17 to 2020 (↑ price).....	6.65	5	Fentanyl Sandoz
	Patch 75 mcg per hour – 1% DV Oct-17 to 2020 (↑ price).....	9.25	5	Fentanyl Sandoz
	Patch 100 mcg per hour – 1% DV Oct-17 to 2020 (↑ price)....	11.40	5	Fentanyl Sandoz
115	MORPHINE SULPHATE (pack size change and addition of HSS)			
	Inj 1 mg per ml, 100 ml bag – 1% DV Oct-17 to 2020	97.25	5	Biomed
	Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-17 to 2020	24.00	5	Biomed
	Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-17 to 2020	50.75	5	Biomed
Note – Biomed inj 1 mg per ml, 100 ml bag, 1 mg per ml, 10 ml syringe and 1 mg per ml, 50 ml syringe, 10 inj pack to be delisted from 1 October 2017.				
116	REMIFENTANIL HYDROCHLORIDE (brand change and amended chemical name)			
	Inj 1 mg vial – 1% DV Oct-17 to 2020	13.95	5	Remifentanil-AFT
	Inj 2 mg vial – 1% DV Oct-17 to 2020	19.95	5	Remifentanil-AFT
Note – Ultiva inj 1 mg and 2 mg vial to be delisted from 1 October 2017.				

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

144	IMATINIB MESILATE (↓ price and addition of HSS)			
Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule				
	Cap 100 mg – 1% DV Oct-17 to 2020	98.00	60	Imatinib-AFT
	Cap 400 mg – 1% DV Oct-17 to 2020	197.50	30	Imatinib-AFT
147 PACLITAXEL (↑ price and addition of HSS)				
	Inj 6 mg per ml, 5 ml vial – 1% DV Oct-17 to 2020	47.30	5	Paclitaxel Ebewe
	Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-17 to 2020	20.00	1	Paclitaxel Ebewe
147 PACLITAXEL (↓ price and addition of HSS)				
	Inj 6 mg per ml, 50 ml vial – 1% DV Oct-17 to 2020	35.35	1	Paclitaxel Ebewe



(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST)	Brand or Generic Manufacturer
	\$	Per

Changes to Section H Part II – effective 1 August 2017 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

190 IPRATROPIUM BROMIDE (↑ price and addition of HSS)
Aqueous nasal spray 0.03% – **1%** DV Oct-17 to 2020 4.61 15 ml Univent

Effective 1 July 2017

NERVOUS SYSTEM

116 MORPHINE SULPHATE (Pharmacode change)
Tab immediate-release 10 mg – **1%** DV Sep-17 to 2020..... 2.80 10 **Sevredol**
Tab immediate-release 20 mg – **1%** DV Sep-17 to 2020..... 5.52 10 **Sevredol**

Note – this is a change from a bottle to blister pack (2520990 and 2521008 respectively). The bottle packs are to be delisted 1 October 2017.

Index

Pharmaceuticals and brands

A	
Accu-Chek Ketur-Test	7
Aminophylline	7
Amoxicillin with clavulanic acid	9
Apo-Nicotinic Acid	8
Apo-Propranolol.....	5
Apo-Pyridoxine	7
A-Scabies	8
Augmentin	9
Azactam	9
Aztreonam	9
B	
Bisoprolol fumarate	8
Bosvate	8
C	
Celecoxib.....	9
Celecoxib Pfizer.....	9
Citrate sodium.....	7
Clarithromycin.....	9
Clexane.....	5
Colecalciferol.....	7
Co-trimoxazole	9
D	
DBL Aminophylline	7
DBL Ergometrine	5
DBL Octreotide	6
Deprim.....	9
Desmopressin acetate	9
Desmopressin-PH&T.....	9
Dexamethasone phosphate.....	8
Dextrose	8
E	
Emulsifying ointment.....	8
Enoxaparin sodium.....	5
Ergometrine maleate	5
Etoricoxib.....	9
F	
Fentanyl	10
Fentanyl Sandoz.....	10
Flamazine.....	8
Floair	6
Fluticasone	6
Fluticasone with salmeterol	6
G	
Glucose [dextrose]	8
I	
Imatinib-AFT	10
Imatinib mesilate	10
Ipratropium bromide.....	11
Ismo-20.....	8
Isosorbide mononitrate	8
Ispaghula (psyllium) husk.....	7
K	
Ketostix.....	7
Klacid	9
Konsyl-D.....	7
L	
Lidocaine [lignocaine] hydrochloride	10
Lignocaine	10
Losartan Actavis	5
Losartan potassium.....	5
M	
Meterol	6
Metformin hydrochloride	5
Morphine sulphate.....	10, 11
Mucosothe.....	10
N	
Naprosyn SR 750.....	10
Naprosyn SR 1000.....	10
Naproxen	10
Neostigmine metilsulfate	6
Nicotinic acid	8
Nilstat	7
Nystatin	7
O	
Octreotide	6
Oestriol	8
Oseltamivir.....	6
Ovestin	8
P	
Paclitaxel	10
Paclitaxel Ebewe	10
Pegasys.....	9
Pegasys RBV Combination Pack	9
Pegylated interferon alfa-2A.....	9
Peptisothe	7
Permethrin	8
Pinetarsol.....	8
Pine tar with trolamine laurilsulfate and fluorescein..	8
Piperacillin with tazobactam	6
Prednisolone acetate	7
Prednisolone- AFT	7
Propranolol	5
Pyridoxine hydrochloride	7
R	
Ranitidine	7
Ranitidine Relief	7
Relenza Rotadisk	6
Remifentanil.....	10
Remifentanil-AFT.....	10
Remifentanil hydrochloride	10
RexAir.....	6

Index

Pharmaceuticals and brands

S	
Salmeterol	6
Sevredol	11
Sodium chloride.....	5
Sodium nitroprusside	7
Sulfadiazine silver	8
Sulphadiazine silver.....	8
Suxamethonium	6
T	
Trimethoprim with sulphamethoxazole [co-trimoxazole].....	9
U	
Univent	11
V	
Vit.D3	7
Z	
Zanamivir.....	6
Zinc and castor oil.....	5



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.